By Tom Zanki ( February 25, 2015, 5:52 PM EST) -- Xencor Inc., a California biotech developing antibodies to treat autoimmune and allergic diseases and cancer, set terms Wednesday for a follow-on offering that could raise $124.7 million, marking three life sciences companies in two days to announce follow-ons that together surpass $300 million....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.